AlphAIAlphAI — Financial news for AI agents
rttnews.com$HAE

Haemonetics Reports Q2 Fiscal 2027 Results; Raises Full-Year Revenue And Organic Growth Outlook

Haemonetics (HAE) reported Q2 fiscal 2027 revenue growth of 9.3% to $357.8M, with Apheresis up 12.6% and MedSurg up 5.1%. EPS rose 23% to $1.00. The company raised full-year revenue guidance to 8%-11% and organic growth to 6%-9%.

Original reporting
rttnews.com
Published Nov 5, 2026, 2:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 2:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Haemonetics Reports Q2 Fiscal 2027 Results; Raises Full-Year Revenue And Organic Growth Outlook — source image
Source · rttnews.com
Decision brief

The 30-second read

$HAEBullishMed
01

Why it matters

The earnings beat and raised guidance are likely to attract buying interest, though the stock's modest decline suggests some investors remain cautious.

02

Market read

Earnings and guidance update provide fresh material for traders; potential short-term price move.

03

What to watch

Higher debt level ($1.124B) and net debt ($863M) could constrain cash flow if growth slows.

Relevance 8/10Novelty 8/10Timing: post-market release

Background

Haemonetics reported Q2 FY2027 results, showing revenue growth across segments and raised full-year outlook.

Company-level read

Ticker impact

$HAEBullishHigh confidence
Context

Q2 fiscal 2027 earnings released with revenue up 9.3% and guidance raised to 8%-11% revenue growth.

Expected impact

modest upside as market prices in higher revenue outlook

Evidence & confidence

Earnings beat and raised guidance typically lift sentiment; stock only down 1.35% at release, leaving room for upside.

Market effects

Sector

Blood-management and medical device sector may see renewed investor interest from HAE's growth outlook.

Regional

U.S. healthcare equities could benefit from the upbeat guidance.

Global

Limited to niche medical device space; no broad market effect.

Counterpoint

What could challenge this read

Guidance raise may already be priced in; execution risk on new product launches could limit upside.

Key entities

  • Company
    Haemonetics Corporation

    Global provider of blood management solutions.

Read at source← All news

StoryHaemonetics posts Q2 FY2027 earnings beat and lifts full‑year revenue outlook

Also covered by

4 outlets

Related articles

$HAEMed

Mizuho raises Haemonetics stock price target on plasma strength

Mizuho raised its price target for Haemonetics (HAE) to $165 from $140, citing 18% organic plasma growth and improved guidance. The stock has gained 151% over the past year. HAE reported Q2 earnings of $1.35 per share, beating estimates, with revenue up 9.3% YoY. BTIG also raised its target to $142. Investors note margin guidance concerns and growth spending.

investing.com
$HAEHighAI 8/10

BTIG raises Haemonetics stock price target to $142 on earnings beat

BTIG raised its price target on Haemonetics (HAE) to $142 from $130, maintaining a Buy rating. HAE's Q2 2027 revenue was $357.8M, up 9.3% YoY, beating estimates. Adjusted EPS was $1.35, exceeding expectations. All segments performed well, with Apheresis revenue at $204.8M. Adjusted gross margin increased to 61.9%. HAE raised fiscal 2027 revenue guidance but reduced adjusted EBIT margin expansion outlook.

investing.com